Pharming Group N.V. (PHAR) announced, for the full year 2023, total revenues are expected to increase by 19% to approximately $245 million. For 2023, the company expects RUCONEST revenues to increase by 10% to approximately $227 million. For the full year 2023, the company expects Joenja revenues of approximately $18 million.
"We expect 10% growth in RUCONEST revenues, significantly exceeding our previous guidance for low single digit annual revenue growth. We launched Joenja for APDS in the U.S. in April, shortly after FDA approval, and saw fast uptake from patients for the first and only FDA approved treatment for APDS," said Sijmen de Vries, CEO.
Preliminary, unaudited cash and cash equivalents, together with restricted cash and marketable securities, are projected to total $215.0 million at the end of 2023.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.